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Abstract
Background: This study compared diagnostic methods for identifying Blastocystis in stool samples, and evaluated the
frequency of detection of Blastocystis in patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
Results and Discussion: From a set of 105 stool specimens submitted for routine parasitological analysis, 30 were identified
as positive for Blastocystis by the culture method. From that group of 30 positives, Lugol’s stain, trichrome staining, and an
immunofluorescence assay identified 11, 15, and 26 samples as positive respectively. Using culture as a standard, the
sensitivity of Lugol’s stain was 36.7%, trichrome staining was 50%, and the IFA stain was 86.7%. The specificity of Lugol’s
stain was 91%, trichrome staining was 100%, and the IFA stain was 97.3%. In the group of 27 IBS and IBD patients, using all
methods combined, we detected Blastocystis in 67% (18/27) of the patients. Blastocystis was detected in 33% (2/6) of IBD
patients and 76% (16/21) of IBS patients. For comparison, trichrome staining alone, the method most frequently used in
many countries, would have only identified Blastocystis infection in 29% (6/21) of the IBS patients. No parasitic co-infections
were identified in the IBS/IBD patients. Most Blastocystis-positive IBS/IBD patients were over 36 with an average length of
illness of 4.9 years.
Conclusions: Most IBS patients in this study were infected with Blastocystis. IFA staining may be a useful alternative to stool
culture, especially if stool specimens have been chemically preserved.
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Introduction
Blastocystis is a single-celled parasite that infects the lower
gastrointestinal tract of humans and animals. It is one of the few
enteric parasites with a prevalence that often exceeds 5% in the
general population of developed countries [1,2], and exceeds 40%
in individuals with chronic gastrointestinal illness [3,4,5]. Symp-
tomatic infection with Blastocystis has been associated with
abdominal pain (88%), diarrhea (23%), and constipation (32%)
[6]. Additional symptoms reported include vomiting (13%), fatigue
(11%), headaches, skin rashes, joint pain, and psychiatric illness
[2,7]. The majority of symptomatic Blastocystis cases occur in
immunocompetent individuals [8] in the absence of any parasitic
co-infection [9,10]. Clinical diagnosis of Blastocystis infection is
customarily performed with microscopical examination of stained,
chemically preserved stool specimens, despite that method’s lack of
sensitivity [11].
Researchers have noted the need for reliable tests for Blastocystis
to diagnose patients and to distinguish therapies which eradicate
the organism from those that provide temporary symptomatic
improvement [12]. Prior studies have compared the sensitivity of
conventional staining techniques to commercially available assays
in coprological detection of other unicellular enteric protists, such
as Giardia lamblia, Cryptosporidium parvum, and Entamoeba histolytica
[13,14,15,16]. Such studies have often suggested that conventional
staining techniques fail to identify many infections.
Antibodies Inc. (Davis, California, USA) and Savyon Diagnos-
tics (Israel) have announced an immunofluorescence (IFA) assay
and ELISA test respectively for the detection of Blastocystis. At the
time of this study, only the IFA assay was available for evaluation.
Following the methodology of prior studies of enteric protozoa, we
compared the results obtained through the use of different
diagnostic methods for Blastocystis when applied to stool samples
submitted for routine parasitological analysis [13,14,15]. Prior
studies have suggested that stool culture may be the most sensitive
method available for Blastocystis [10,17], so we used stool culture as
a standard against which to evaluate the sensitivities of other
detection methods.
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Irritable bowel syndrome (IBS) and inflammatory bowel disease
(IBD) are chronic gastrointestinal illnesses of unknown causes
which are common in developed countries. Symptoms of IBS are
abdominal pain (100%), diarrhea (25%), and constipation (24%)
[18]. Additional symptoms include vomiting, fatigue, headaches,
and psychiatric symptoms [7]. IBS is the seventh most frequent
diagnosis given to patients visiting primary care physicians [19],
and studies of IBS prevalence have reported that 20–50% of
referrals to gastroenterologists are due to IBS [18]. Although IBS is
frequently identified as a psychosomatic disease, a number of
studies have reported that many or most IBS patients can be
shown to carry well established pathogenic gastrointestinal proto-
zoa, or protozoa which can be shown to cause similar gastrointes-
tinal illness in experimental animal infection [20,21,22,23,24].
Blastocystis has also been identified in association with intestinal
inflammation [25] and IBD [26,27,28]. In the second part of the
study, we tested stool samples from a group of IBS and IBD patients
for Blastocystis using culture, conventional staining and IFA staining.
Neurological symptoms in IBS patients have traditionally been
attributed to psychiatric causes, but a series of studies has identi-
fied an organic etiology by demonstrating that colonic biopsies
from IBS and IBD patients secrete high levels of a trypsin-like
serine protease [29]. Supernatants from the biopsies produced
neurological symptoms when introduced into gastrointestinal
tracts of mice by hypersensitizing neurons through the protease-
activated (PAR2) pathway. The elevated trypsin-like protease
production was found in all diarrhea-predominant and constipa-
tion-predominant IBS patients and IBD patients in multiple
geographies by different research groups [29,30,31], but is absent
in patients with viral and bacterial enteritis [31]. Researchers have
not determined if the trypsin-like protease is endogenous or
microbial in origin. In this study, we investigated biopsies from IBS
and IBD patients for the presence of Blastocystis infection to try to
evaluate the etiology of the trypsin-like protease.
Materials and Methods
Study subjects and specimens
For the evaluation of assay sensitivity and specificity, 105 stool
samples submitted for parasitological analysis to the Gazi University
School of Medicine were evaluated. As is consistent with prior
studies in the evaluation of assay performance[13,14,15],the health
histories from patients submitting those samples were not a focus of
this study, but participant age, sex, year of onset, and illness has
been included in supplemental file S1.
The second part of the study followed the methodologies used in
prior studies which have evaluated the prevalence of Blastocystis
infection [5,22,32] or other physiologically relevant phenomenon
[29] in patients with illness diagnosed as IBS or IBD. Patients
undergoing clinical evaluation at the Gazi University School of
Medicine and Yildirim Beyazit Education and Research Hospital,
Department of Gastroenterology, Ankara, Turkey were invited to
participate in the study. IBS patients satisfied the Rome III criteria
[33]. IBD patients were diagnosed with ulcerative colitis or
Crohn’s disease by clinical manifestation, sigmoidoscopy, barium
enema, colonoscopy and laboratory analysis [34].
Colonoscopy Procedure. The colonoscopy procedure fol-
lowed the method outlined in a prior study of trypsin production in
IBS/IBD patients [29], except that midazolam (Dormicum: Roche)
was used for sedation. Four biopsies were taken from the rectum.
Two biopsies each were taken from the ascending, transverse, and
descending colon.
Fecal culture. Unpreserved fecal specimens were cultured in
Ringer’s solution containing 10% horse serum and 0.05% asparagine
at 37uC for 3–4 days, and screened with direct microscopy.
Conventional Staining. Fecal specimens were evaluated
with Lugol’s stain and trichrome staining [35].
IFA Staining. Fecal specimens were evaluated with Blasto-
Fluor (Antibodies Inc., Davis, California), a commercially avail-
able immunofluorescence antibody (IFA) stain specific for
Blastocystis, which was a gift from the manufacturer. Blasto-Fluor
staining was performed by combining 200 ml of the fecal sample,
200 ml of phosphate buffered saline (PBS) and 4 ml of stain, then
incubating for 60 minutes at 37uC. The sample was viewed under
a fluorescence microscope using a 495 nm excitation filter and a
515 nm barrier filter. According to the manufacturer, the Blasto-
Fluor stain was prepared from whole cell Blastocystis antigen from
an American Tissue and Culture Collection (ATCC) culture
identified as Blastocystis sp. subtype 3. The stain was prepared using
a method similar to that reported in a 1993 United States National
Institutes of Health paper [36]. The manufacturer’s data sheet
indicated no cross-reactivity to E. histolytica, Giardia lamblia,
Cryptosporidium parvum, Dientamoeba fragilis,o rSaccharomyces cerevisiae,
and the NIH paper noted lack of cross-reactivity with ‘‘bacterial,
fungal, and mammalian cells’’ [36]. We verified the stain showed
no cross reactivity with Giardia lamblia, Entamoeba coli, Candida,
human leukocytes, and human erythrocytes.
Biopsy Examination. Colonic biopsies were evaluated with
the IFA stain as described previously in the procedure for stool
samples. The biopsies were then compressed under a cover slip,
and examined under a fluorescence microscope using the method
described previously for stool specimens.
Statistical analysis. Statistical analysis was performed using
the Statistical Package for the Social Sciences 13.0 software package.
McNemar’s test was applied to compareresults from culture to other
tests, and Pearson correlation coefficients were reported for all
comparisons. Fisher’s Exact Test was used to assess the significance
of relationship between Blastocystis and IBS. A probability value of
less than 0.05 was considered statistically significant.
Ethics and conflict of interest. Written informed consent
wasobtained fromallstudysubjects.The studywasapproved bythe
Gazi University School of Medicine’s Local Ethical Committee. All
laboratory work was performed at the Department of Medical
Microbiology Laboratory, Gazi University School of Medicine.
Antibodies Inc. provided the IFA stain used in the study, but
otherwise did not participate in or influence the design of the study,
handling of samples, interpretation of the data, or the manuscript
preparation.
Results
In the collection of 105 stool samples, Blastocystis was detected in
28.6% (30/105) of the samples with stool culture (File S1). Of the
30 samples positive by culture, Lugol’s stain, trichrome staining,
and IFA staining identified 11, 15, and 26 samples as positive
respectively. Using culture as a standard, the sensitivity of Lugol’s
stain was 36.7%, trichrome staining was 50%, and the IFA stain
was 86.7%. The specificity of Lugol’s stain was 91%, trichrome
staining was 100%, and the IFA stain was 97.3%. Sensitivity was
calculated as TRUE_POSITIVES/(TRUE_POSITIVES + FALSE_
NEGATIVES). Specificity was calculated as TRUE_NEGATIVES/
(TRUE_NEGATIVES + FALSE_POSITIVES). Thus, a test with no
false negatives would have a sensitivity of 100%, while a test
with no false positives would have a specificity of 100%. File S2
contains cross-tabulation tables with McNemar’s test and
Pearson correlation data.
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IBS and 6 with IBD, with 17 females, and 10 males. Patients
ranged in age from 19 to 76 with a median age of 42. The earliest
date of illness onset reported was 1995, and the most recent date
was 2009. The average length of illness was 4.9 years. Most
patients reported illness beginning after 2000. Using all methods
combined, we detected Blastocystis in 67% (18/27) of the patients
(Table 1). Blastocystis was detected in 33% (2/6) of the patients with
IBD, and in 76% (16/21) of IBS patients.
While this study did not include a healthy control group, prior
study performed at this site with Lugol’s staining has identified the
prevalence of Blastocystis infection in healthy controls at 11.6% (5/
43) [1]. Comparing the results from Lugol’s staining, we identified
a statistically significant increase in Blastocystis infection in IBS
patients over healthy controls, with 38% (8/21) of the IBS patients
having Blastocystis infection vs. 11.6% (5/43) of the healthy controls
(p=0.0208, Fisher’s Exact Test, two-tailed) [1].
Examination of biopsies generally failed to show Blastocystis,e v e ni n
patients with positive stool tests. However one IBS patient (4.7%, 1/21)
tested negative for Blastocystis by all coprological methods, while the
biopsy showed the presence of Blastocystis (Table 1, patient Z-16).
No other parasitic infections, such as Giardia lamblia or E.
histolytica, were detected in trichrome staining of stool samples from
the IBS/IBD group.
Discussion
We were able to identify Blastocystis in patients using common
laboratory methods. But a standard method used in clinical practice,
trichrome staining, did not perform well. The low sensitivity of this
method has been reported in prior studies from Thailand [17], United
Kingdom [37], Denmark [10], and the United States [38]. Prior
studies have attributed the difficulty of identifying Blastocystis to its large
number of morphological forms [11], the large size variation exhibited
by the organism [7], or its similarity in appearance to a fat cell [11].
Comparison of techniques
In our study, relative to stool culture, the IFA stain provided a
sensitivity of 86.7% and specificity of 97.3%, an improvement over
Table 1. Blastocystis testing results from patients with IBS and IBD.
Blastocystis detected in stool with...









BL detected in colonic biopsy
with IFA stain, #cells/field
1 Z-10 44 F IBS-D 2009 4-5 ++ + -
2 Z-11 42 M IBS-D 2008 - - - 0-1 +
3 Z-18 38 M IBS-D 2008 - - + --
4 Z-25 56 M IBS-D 2006 - - - S -
5 G-3 26 M IBS-D 2008 - - + --
6 G-12 39 F IBS-D 2009 - - + 10-15 0-1
7 Z-1 36 M IBS-C 2000 3-4 ++ --
8 Z-4 46 F IBS-C 2004 - - - - -
9 Z-5 52 M IBS-C 1998 S - - - -
10 Z-7 56 F IBS-C 2001 - - - - -
11 Z-12 46 F IBS-C 2002 1-2 + -4 - 6 -
12 Z-32 26 M IBS-C 2006 - - - - -
13 Z-59 47 F IBS-C 1995 - - - - S
14 G-15 40 F IBS-C 2008 - ++ 8-10 -
15 Z-3 50 F IBS-A 2006 - - - - -
16 Z-9 29 F IBS-A 2007 S - - - -
17 Z-16 25 F IBS-A 2008 - - - - 0-1
18 Z-21 44 F IBS-A 2007 0-1 ++ 0-1 -
19 Z-49 40 F IBS-A 2008 2-3 ++ 10-15 -
20 G-9 38 M IBS-A 2006 - - - - -
21 G-11 48 F IBS-A 2007 1-2 ++ 2-3 -
22 Z-36 46 M IBD (UC) 2009 4-5 ++ 5-8 -
23 G-4 19 F IBD (UC) 2008 - - - - -
24 G-21 76 M IBD (UC) 1996 0-1 - - - 1
25 G-13 55 F IBD 2000 - - - - -
26 G-14 27 F IBD 2008 - - - - -
27 G-17 40 F IBD 2006 - - - - -
Total 10 8 10 10 5
Numbers shown represent numbers of organisms per field. IBS-D, IBS-C and IBS-A refer to diarrhea-predominant IBS, constipation predominant IBS, or alternating
diarrhea/constipation IBS. UC refers to Ulcerative Colitis. S=Organisms identified which are suspected to be Blastocystis, but were difficult to identify due to a distorted
morphological form or light staining. These were counted as positives in compiling statistics.
doi:10.1371/journal.pone.0015484.t001
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The IFA stain has the advantage of providing a result in
approximately one hour, instead of the 3–4 days required for
culture. The method does not require the training associated with
stool culture, trichrome staining or PCR analysis.
Molecular diagnostics like this one, which provide a clearer
visual indicator of positive or negative status (figure 1), may help
provide some consistency between different labs, possibly address-
ing regional disagreements [7] concerning the importance of the
organism in disease. A comparison among European reference
laboratories found that Blastocystis was the most inconsistently
detected enteric protozoan. From a shared set of 102 samples, one
reference laboratory identified 25 samples as Blastocystis-positive,
while another reference laboratory identified 90 samples as
Blastocystis-positive [39]. A similar study between two European
diagnostic centers with sub-specialties in tropical medicine
reported that when each was given a set of 48 stool samples
prepared to be identical in parasitological content, one center
identified 29 as Blastocystis-positive, while the other identified 38 as
positive. A further comparison between one of the European
diagnostic centers and a West African center using 78 stool
samples collected from identical patients but on different days
found that the European center identified 38 as Blastocystis-positive,
while the West African center identified 7 as positive [40].
Substantial differences were also found in the detection of
Entamoeba histolytica/dispar, though not as great as those seen in
the detection of Blastocystis.
Staining of formalin-preserved specimens (vs. unpreserved
specimens) with the IFA stain appeared to produce no loss in
sensitivity (data not shown). The culture and PCR methods have
not been shown to be compatible with chemically preserved
specimens. While we did not test the stability of the stool antigen,
the IFA stain’s manufacturer reported that 6-month old formalin-
preserved stool specimens stain successfully. The IFA assay offers
cost advantages over PCR [10], although it does not provide
information about Blastocystis genotype. While the IFA method
offers an improvement over existing laboratory techniques, it was
still unable to detect some infections, possibly because it requires
the presence of whole or partial cells in the sample.
Some culture-positive samples were judged negative on the IFA
staining portion of the study, however closer examination showed
the presence of lightly stained, irregularly formed cells. A detailed
investigation of the phenomenon is beyond the scope of this study.
No single diagnostic method could have identified all of the
infections found in IBS patients (Table 1), although stool culture
would have identified the largest number of infections we found.
PCR has been suggested for clinical diagnosis of Blastocystis
infection [10], but PCR testing offers challenges as well, as a prior
Blastocystis study found that PCR failed to detect 25% of samples
positive by culture due to PCR inhibitors in stool samples [41]. A
lower sensitivity of PCR compared to stool culture was also found
in a Pakistani study of IBS patients [22]. Some inherent limitations
may exist in the use of coprological tools to investigate Blastocystis
infection: experimental infection of mice has suggested Blastocystis
cells may embed themselves deep in the gastrointestinal tract,
reaching muscle layers [42], and also survive for long periods of
time in immunocompetent animals outside of the gastrointestinal
tract [43].
Blastocystis in IBS patients
We report that most IBS patients (76%) in our study were infected
with Blastocystis, which we previously showed generally consists of
subtypes 2 and 3 in Ankara, Turkey [26]. The finding of elevated
frequency of Blastocystis infection is similar to prior studies from
Pakistan [3], the United Kingdom [4], and Italy [32] (Table 2). A
recent study from Pakistan identified Blastocystis infection in 53% (90/
171), and Dientamoeba fragilis in 4% (7/171) of diarrhea-predominant
IBS patients by stool culture [22]. That study specifically excluded
patients with Giardia lamblia, Entamoeba histolytica, Salmonella spp.,
Campylobacter jejuni, Clostridium difficile,a n dVibriocholerae. Our finding of
symptomatic Blastocystis mono-infection is consistent with prior
research from Canada [8], Denmark [10], France [41], Egypt [41],
Australia [44], Jordan [45], and the United States [38,46].
Prior study has suggested that the type of disease found in IBS
and IBD patients is dissimilar to bacterial or viral enteritis, as
patients with the later diseases do not express the high levels of
trypsin-like compound that are found in fecal specimens from
IBS/IBD patients [31]. As the production of such a trypsin-like
compound by colonic biopsies is present in all IBS/IBD patients,
but is of unknown origin [29,30,31], the biopsy data from this
study may help elucidate the source of that compound. Since most
biopsies did not show Blastocystis, we suggest that this organism is
Figure 1. Stool sample stained with IFA stain, comparing bright field (left) and fluorescence microscope view (right) showing
Blastocystis. High resolution photomicrographs courtesy of Antibodies Inc.
doi:10.1371/journal.pone.0015484.g001
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human body have been recently found to produce trypsin-like
compounds. The production may be related to the innate immune
activation found in IBS/IBD patients [47,48,49].
Blastocystis in IBD patients
We detected Blastocystis infection in a third of the IBD patients,
although the size of the IBD group was small. A prior study from
Mexico identified Blastocystis in 10% of IBD patients [27], and
noted presence of Blastocystis, E. histolytica,o rEntamoeba coli was
correlated with relapsing illness [27].
Parasite quantity in Blastocystis infection
Blastocystis is the only common intestinal parasite where the
number of organisms per field is represented as medically
significant [7], and studies have suggested that Blastocystis simply
‘‘overgrows’’ in response to some other type of illness. We were
unable to demonstrate any kind of consistent Blastocystis over-
growth in these IBS/IBD patients. Although Blastocystis was found
consistently, few of the IBS and IBD patients had large quantities
of Blastocystis in stool samples. Parasite quantity in stool samples is
generally uncorrelated with symptomatic severity in enteric
infections in humans, so sensitive PCR and ELISA tests are
employed to diagnose diseases such as giardiasis or ameobiasis
[50]. Other papers have addressed the mechanisms underlying
such symptomatic expression in protozoal illness [51,52,53]. A
review of research is beyond the scope of this paper, however
pathogenic protozoa express ligands which become physiologically
reactive at low concentrations [51,52,53] in hosts that do not
express IgA antibodies to them. Hosts may fail to express IgA due
to lack of prior exposure, or the presence of host genetic mutations
in Toll-like receptor genes and cytokine expression, such as those
which have been found in IBS and IBD patients [54,55]. Protozoal
ligands may interfere with the host’s adaptive immune response,
producing long-term infection and symptoms [52,56].
Clinical Significance of Blastocystis in IBS Patients
Blastocystis was associated with IBS as early as 1986, when a US
study attributed gastrointestinal illness in patients mono-infected
with Blastocystis to IBS, in support of the hypothesis that Blastocystis
was non-pathogenic [57]. By 1997, researchers had begun
reporting the appearance of Blastocystis infection at statistically
significant rates in patients with IBS and chronic gastrointestinal
illness in Pakistan [3], Italy [32], and the United Kingdom [4],
with public health officials urging that Blastocystis be excluded
before diagnosing patients with IBS [58]. IBS ‘‘outbreaks’’ have
included returning international travelers to the US [59], a
community exposure to contaminated water in Canada [60,61],
and IBS-like illness in association with military service in the
Persian Gulf [62].
Host factors, such as age, have been suggested as contributing to
the expression of symptoms in Blastocystis infection [7,26]. In our
study, 68% (19/28) of the IBS/IBD patients were between the
ages of 38 and 56. The median age of the study’s patient
population was 42, 15 years older than the median age of Turkey’s
population. While the age distribution of participants in a
voluntary study can be influenced by self-selection, a number of
other studies have noted age relationships. A study of Blastocystis in
158 diarrhea-predominant (IBS-D) patients in Pakistan [5]
reported a mean age of 41. A histogram describing symptomatic
Blastocystis infection in a 1990 Canadian study of 143 patients
showed a peak in infection rates in patients who were 33–34 years
of age [8]. Prior studies have noted differences in symptomatic
expression of Blastocystis based on age [45].
Conclusions
Most Blastocystis infections are not detectable in stool samples
with conventional staining techniques, and most IBS patients in
this study were infected with Blastocystis. Stool culture and IFA
staining provide better sensitivity than conventional staining
techniques, but still fail to detect infection in some symptomatic
patients. IFA staining provides a more sensitive method than
conventional staining for identifying Blastocystis infection in
chemically preserved stool samples.
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